It’s only fair to share… Bimokalner CAS 2243284-19-5 MF C15H18F5NOS MW 355.4 g/mol (1S,2S,4R)-N-{[3-(pentafluoro-λ6sulfanyl)phenyl]methyl} bicyclo[2.2.1]heptane-2-carboxamidevoltage-gated potassium channel (Kv7.4) agonist Bimokalner is an investigational new drug under evaluation for preventing and treating hearing loss caused by cisplatin treatment. It is a voltage-gated potassium channel agonist targeting Kv7.4 and is being developed by Acousia Therapeutics GmbH.[1][2] PAT Compounds useful as potassium channel openers, Publication Number: US-11884642-B2, Priority Date: 2017-02-28, Grant Date: 2024-01-30 …